Janssen Biotech's SYLVANT (siltuximab) Garners FDA Approval
According to a release, SYLVANT was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT did not bind to virally produced interleukin-6 in a nonclinical study.
No comments:
Post a Comment